← back to search

John McNally

Augusta University · US
Area of research
Hepatology · Infectious Diseases
Research interest
Research interests include Hepatitis C virus research, HIV/AIDS drug development and treatment, Ocular Surface and Contact Lens, and Corneal surgery and disorders.
h-index
34
citations
8,898
works
94
NIH funding
primary concept
Medicine
email

Recent publications

Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial
The Lancet 2021cited by 431position: middledoi
Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study
Clinical Infectious Diseases 2017cited by 158position: middledoi
Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses
Journal of Hepatology 2017cited by 134position: middledoi
Resistance analysis in patients with genotype 1–6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies
Journal of Hepatology 2017cited by 96position: middledoi
Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials
Clinical Infectious Diseases 2016cited by 91position: middledoi
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection
New England Journal of Medicine 2015cited by 1,110position: middledoi
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
New England Journal of Medicine 2015cited by 846position: middledoi
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis
New England Journal of Medicine 2015cited by 802position: middledoi
Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection
Annals of Internal Medicine 2015cited by 96position: middledoi
Concordance of sustained virological response 4, 12, and 24 weeks post‐treatment with sofosbuvir‐containing regimens for hepatitis C virus
Hepatology 2014cited by 196position: middledoi
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
New England Journal of Medicine 2013cited by 1,780position: middledoi
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
New England Journal of Medicine 2013cited by 1,081position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Diana M. Brainard · Gilead Sciences (France)10 papers (2013–2017)John G. McHutchison · Gilead Sciences (United States)7 papers (2013–2017)Anu Osinusi · Gilead Sciences (United States)5 papers (2015–2017)Ira M. Jacobson · NYU Langone Health5 papers (2013–2017)Brian Doehle · Gates Foundation4 papers (2015–2017)K. Rajender Reddy · Fred Hutch Cancer Center4 papers (2013–2015)Mark Sulkowski · Johns Hopkins Bayview Medical Center4 papers (2013–2017)Eric Lawitz · Indiana University – Purdue University Indianapolis4 papers (2013–2015)Alessandra Mangia · NIHR Birmingham Biomedical Research Centre3 papers (2013–2016)Stefan Zeuzem · Heidelberg University3 papers (2015–2017)William T. Symonds · Gilead Sciences (United States)3 papers (2013–2014)Jordan J. Feld · University Health Network3 papers (2013–2016)Eric M. Yoshida · Ohio University3 papers (2013–2015)G. Mani Subramanian · Pacific Biosciences (United States)3 papers (2013–2016)Edward Gane · New Zealand Christians in Science3 papers (2013–2015)Evguenia S. Svarovskaia · Gilead Sciences (United States)3 papers (2015–2017)Hongmei Mo · Gilead Sciences (United States)2 papers (2017–2017)Stuart K. Roberts · The Alfred Hospital2 papers (2015–2017)Mitchell L. Shiffman · Bon Secours Health System2 papers (2013–2015)Charlotte Hedskog · Gilead Sciences (United States)2 papers (2017–2017)